Rezultati - Filip Baert

Refine Results
  1. 1
    Retrograde Cricopharyngeus Dysfunction, a New Motility Disorder: Single Center Case Series and Treatment Results

    Retrograde Cricopharyngeus Dysfunction, a New Motility Disorder: Single Center Case Series and Treatment Results od Stijn Arnaert, Joris Arts, Karlien Raymenants, Filip Baert, Kathelijne Delsupehe

    Izdano 2024
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  2. 2
    Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice

    Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice od Cathérine Reenaers, Peter Bossuyt, P. Hindryckx, Hilde Vanpoucke, Anneline Cremer, Filip Baert

    Izdano 2018
    Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  3. 3
    Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum

    Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum od Geert D’Haens, Karel Geboes, Marc Peeters, Filip Baert, Freddy Penninckx, P. Rutgeerts

    Izdano 1998
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  4. 4
    Clinical Trials in Ulcerative Colitis: A Historical Perspective

    Clinical Trials in Ulcerative Colitis: A Historical Perspective od Pieter Hindryckx, Filip Baert, Ailsa Hart, Fernando Magro, Alessandro Armuzzi, Laurent Peyrin–Biroulet

    Izdano 2015
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  5. 5
    Familial aggregation in Crohn's disease: Increased age-adjusted risk and concordance in clinical characteristics

    Familial aggregation in Crohn's disease: Increased age-adjusted risk and concordance in clinical characteristics od Marc Peeters, Hilde Nevens, Filip Baert, Martin Hiele, A Meyer, Robert Vlietinck, P. Rutgeerts

    Izdano 1996
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  6. 6
    Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

    Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease od Séverine Vermeire, M. Noman, Gert Van Assche, Filip Baert, Geert D’Haens, P. Rutgeerts

    Izdano 2007
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  7. 7
    Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

    Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease od Filip Baert, Maja Noman, Séverine Vermeire, Gert Van Assche, Geert D' Haens, An Carbonez, Paul Rutgeerts

    Izdano 2003
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  8. 8
    Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis

    Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis od Konstantinos Papamichael, Filip Baert, Sophie Tops, Gert Van Assche, Paul Rutgeerts, Séverine Vermeire, Ann Gils, Marc Ferrante

    Izdano 2016
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  9. 9
    Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy

    Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy od Filip Baert, David Drobne, Ann Gils, Niels Vande Casteele, Scott Hauenstein, Sharat Singh, S. Lockton, Paul Rutgeerts, Séverine Vermeire

    Izdano 2014
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  10. 10
    Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis

    Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis od Filip Baert, Niels Vande Casteele, Anita Bengtsson Tops, Maja Noman, Gert Van Assche, P. Rutgeerts, Ann Gils, Séverine Vermeire, Marc Ferrante

    Izdano 2014
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  11. 11
    Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients

    Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients od Filip Baert, E Glorieus, Cathérine Reenaers, Geert D’Haens, Harald Peeters, D Franchimont, Olivier Dewit, Philippe Caenepeel, Édouard Louis, Gert Van Assche

    Izdano 2012
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  12. 12
    Lymphocytic colitis: a distinct clinical entity? A clinicopathological confrontation of lymphocytic and collagenous colitis

    Lymphocytic colitis: a distinct clinical entity? A clinicopathological confrontation of lymphocytic and collagenous colitis od Filip Baert, Karel Wouters, Geert D’Haens, P Hoang, Serge Naegels, F D’Heygere, J Holvoet, E Louis, Martine Devos, Karel Geboes

    Izdano 1999
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  13. 13
    Efficacy of infliximab in refractory pouchitis and Crohnʼs disease-related complications of the pouch: A Belgian case series

    Efficacy of infliximab in refractory pouchitis and Crohnʼs disease-related complications of the pouch: A Belgian case series od Marc Ferrante, Geert D’Haens, Olivier Dewit, Filip Baert, Jan Holvoet, Karel Geboes, Gert De Hertogh, Gert Van Assche, Séverine Vermeire, Paul Rutgeerts

    Izdano 2009
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  14. 14
    Endoscopic and histological healing with infliximab anti–tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial

    Endoscopic and histological healing with infliximab anti–tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial od Geert D’Haens, Sander van Deventer, Ruud van Hogezand, Douglas M. Chalmers, C Kothe, Filip Baert, Tanja Braakman, T Schaible, Karel Geboes, Paul Rutgeerts

    Izdano 1999
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  15. 15
    Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial

    Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial od Gert Van Assche, Charlotte Magdelaine–Beuzelin, Geert D’Haens, Filip Baert, Maja Noman, Séverine Vermeire, David Ternant, Hervé Watier, Gilles Paintaud, Paul Rutgeerts

    Izdano 2008
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  16. 16
    Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover study

    Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover study od Séverine Vermeire, F D’Heygere, A. Nakad, Denis Franchimont, Fernand Fontaine, Édouard Louis, Philippe Van Hootegem, Olivier Dewit, Guy Lambrecht, Beatrijs Strubbe, Filip Baert

    Izdano 2018
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  17. 17
    Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease

    Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease od Filip Baert, Liesbeth Moortgat, Gert Van Assche, Philip Caenepeel, Philippe Vergauwe, Martine De Vos, Pieter Stokkers, Daniël W. Hommes, Paul Rutgeerts, Séverine Vermeire, Geert D’Haens

    Izdano 2009
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  18. 18
    Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis

    Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis od William J. Sandborn, Filip Baert, Silvio Danese, Željko Krznarić, Taku Kobayashi, Xiaopan Yao, Jingjing Chen, Maria Rosario, Siddharth Bhatia, Krisztina Kisfalvi, Geert D’Haens, Séverine Vermeire

    Izdano 2019
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  19. 19
    Epidermal Growth Factor Receptor and K-RAS status in two cohorts of squamous cell carcinomas

    Epidermal Growth Factor Receptor and K-RAS status in two cohorts of squamous cell carcinomas od Nancy Van Damme, Philippe Deron, Nadine Van Roy, Pieter Demetter, Alain Bols, Jo Van Dorpe, Filip Baert, Jean–Luc Van Laethem, Frank Speleman, Patrick Pauwels, Marc Peeters

    Izdano 2010
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  20. 20
    Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease

    Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease od Geert D’Haens, Marc Ferrante, Séverine Vermeire, Filip Baert, Maja Noman, Liesbeth Moortgat, Patricia Geens, Doreen Iwens, Isolde Aerden, Gert Van Assche, Gust Van Olmen, Paul Rutgeerts

    Izdano 2012
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:

Iskalna orodja: